¿Qué interleucinas e inhibidores de IL están involucrados en las vías de la covid-19?
(Which interleukins and il-inhibitors are involved in covid-19 pathways?)
Primeras 5 respuestas:
-
Interleukin-6 (IL-6) is a pleiotropic cytokine with effects in immune regulation, inflammation, and infection.
-
interleukin-6 (IL-6), IL-10, and interferon-gamma (IFN-γ).
-
interleukin-6 (IL-6), IL-10, and interferon-gamma (IFN-γ).
-
IL-6 and IL-6 receptor (IL-6R) inhibition appear to be promising targets for the treatment of COVID-19 patients.
-
Interferon-γ and IL-17 are involved in inducing and mediating proinflammatory responses.
Interleukin-6 (IL-6) is a pleiotropic cytokine with effects in immune regulation, inflammation, and infection.
... Interleukin-6 (IL-6) is a pleiotropic cytokine with effects in immune regulation, inflammation, and infection. The use of drugs that inhibit IL-6 biological activity has been proposed as a treatment for patients with Coronavirus Disease 2019 (COVID-19). The rationale for this approach includes commitment to ...
Ref: Rethinking interleukin-6 blockade for treatment of COVID-19 [Med Hypotheses, 2020]interleukin-6 (IL-6), IL-10, and interferon-gamma (IFN-γ).
... lung infection only. COVID-19 is associated with elevated levels of the inflammatory cytokines such as interleukin-6 (IL-6), IL-10, and interferon-gamma (IFN-γ). Elevated levels of cytokines and the cytokine storm have been linked to fatal disease. This ...
Ref: Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine [Omics, 2020]interleukin-6 (IL-6), IL-10, and interferon-gamma (IFN-γ).
... lung infection only. COVID-19 is associated with elevated levels of the inflammatory cytokines such as interleukin-6 (IL-6), IL-10, and interferon-gamma (IFN-γ). Elevated levels of cytokines and the cytokine storm have been linked to fatal disease. This ...
Ref: Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine. [Omics : a journal of integrative biology, 2020-08-26]IL-6 and IL-6 receptor (IL-6R) inhibition appear to be promising targets for the treatment of COVID-19 patients.
... (IL-6) acts as a key driver of the inflammation associated with coronavirus disease 2019 (COVID-19), IL-6 and IL-6 receptor (IL-6R) inhibition appear to be promising targets for the treatment of COVID-19 patients. It is important to critically analyze the available evidence concerning the use of the available ...
Ref: Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks [BioDrugs, 2020]Interferon-γ and IL-17 are involved in inducing and mediating proinflammatory responses.
... COVID-19. Th1 (IFN-γ), Treg (TGF-ß), and Th17 (IL-17) cytokines concentration were increased in COVID-19 patients. Interferon-γ and IL-17 are involved in inducing and mediating proinflammatory responses. Our data suggest that TGF-ß can be used as a predictive factor of disease severity ...
Ref: Cytokine profile and disease severity in patients with COVID-19 [Cytokine, 2020]lopinavir, methylprednisolone, other symptom relievers, and oxygen therapy.
... standard care recommended by the Diagnosis and Treatment Protocol for Covid-19 (6 th Edition) including lopinavir, methylprednisolone, other symptom relievers, and oxygen therapy. 15 Given the small sample size, we need more research on appropriate dosing. At this ...
Ref: Early Use of Tocilizumab in Respiratory Failure Associated with Acute COVID -19 Pneumonia in Recipients with Solid Organ Transplantation [IDCases, 2020-06-26]interleukin-1 blockers, interleukin-6 inhibitors, Janus kinase inhibitors, in COVID-19.
... randomized clinical trials are currently underway to explore the effectiveness of biopharmaceutical drugs, such as, interleukin-1 blockers, interleukin-6 inhibitors, Janus kinase inhibitors, in COVID-19. The aim of the present paper is to briefly summarize the pathogenetic rationale and the ...
Ref: Role of monoclonal antibody drugs in the treatment of COVID-19 [World J Clin Cases, 2020-10-06]Interleukin-6 (IL-6) drives the inflammatory response in patients with Covid-19 infection
... SESSION TITLE: Fellows" COVID-19 SESSION TYPE: Fellow Case Reports PRESENTED ON: October 18-21, 2020 INTRODUCTION: Interleukin-6 (IL-6) drives the inflammatory response in patients with Covid-19 infection and can sometimes present as cytokine storm Sarilumab, an IL-6 inhibitor may have the potential ...
Ref: Cytomegalovirus Colitis Post Il-6 Inhibitor Use in Covid-19 Infection [Chest, 2020]Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway
... IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients. Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway and thus is likely to become an effective drug for patients with severe COVID-19. ...
Ref: Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality [Int J Antimicrob Agents, 2020]A significant increase in cytokines such as TNF-α, IL-1β, IL-6 and IL-10,
... persistent viral load contributes to the development of T cell abnormalities and cytokine release syndrome. A significant increase in cytokines such as TNF-α, IL-1β, IL-6 and IL-10, as well as chemokines such as CXC-motif chemokine ligand 10 (CXCL10) and CXCmotif chemokine ligand ...
Ref: Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review [Rheumatol Int, 2020-06-26]Baseline interleukin-6 (IL-6) was found to be associated with COVID-19 severity.
... lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin, and D-dimer was found in most severe cases. Baseline interleukin-6 (IL-6) was found to be associated with COVID-19 severity. Indeed, the significant increase of baseline IL-6 was positively correlated with the maximal body temperature ...
Ref: The role of interleukin-6 in monitoring severe case of coronavirus disease 2019 [EMBO Mol Med, 2020]TNF-α, IL-4, IL-6, and IL-12
... spermatogenesis Impaired spermatogenesis via COVID-19 decreases the level of testosterone by disturbing cytokines such as TNF-α, IL-4, IL-6, and IL-12 and further, attenuates the sperm count COVID-19 is causing inflammation via TNF-α and interferons IL-4 ...
Ref: The role of Interleukin-4 in COVID-19 associated male infertility – A hypothesis: Running title: IL-4 and its role in COVID-19 associated male infertility [Journal of Reproductive Immunology, 2020]anti-interleukin-1 (anti-IL-1) and anti-interleukin-6 (anti-IL-6),
... results with hydroxychloroquine have thus far been rather disappointing. Trials with selective cytokine blockers including anti-interleukin-1 (anti-IL-1) and anti-interleukin-6 (anti-IL-6), have shown some promise in more severe cases, with further confirmation being required from large-scale ...
Ref: Emerging pharmacotherapy for COVID-19. [The journal of the Royal College of Physicians of Edinburgh, 2020-06-01]tumor necrosis factor alpha, interleukin 1, interleukin 6, and interferon gamma
... anti‐inflammatory properties. It is a nonselective phosphodiesterase inhibitor and through Adenosine A2A Receptor‐mediated pathways reduces tumor necrosis factor alpha, interleukin 1, interleukin 6, and interferon gamma and may act to reduce tissue damage during the cytokine storm host response to SARS‐CoV‐2 ...
Ref: Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID‐19 patients [Pharmacol Res Perspect, 2020-07-26]Important cytokines involved in this phase are interleukin (IL)-6, IL-1β, and tumor necrosis factor (TNF)-α.
... phase 3 characterized by cytokine storm with worsening respiratory symptoms, persistent fever, and hemodynamic instability. Important cytokines involved in this phase are interleukin (IL)-6, IL-1β, and tumor necrosis factor (TNF)-α. This is typically followed by a recovery phase with production of antibodies against the virus. ...
Ref: Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents [Virol J, 2020-10-15]interferon gamma, interleukin 8 (IL-8), and interleukin 6 (IL-6).
... (SARS-CoV-2) is characterized by elevated serum levels of C reactive protein (CRP) and cytokines, including interferon gamma, interleukin 8 (IL-8), and interleukin 6 (IL-6). Initial reports from the outbreak in Italy, China and the USA have provided anecdotal evidence ...
Ref: Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy [J. immunotherap. cancer, 2020]In this study, we have highlighted the key cytokines induced by coronavirus infections.
... Current researches on COVID-19 continue to highlight the necessity for further understanding the virus-host synergies. In this study, we have highlighted the key cytokines induced by coronavirus infections. We have demonstrated that genes coding interleukins (Il-1α, Il-1ß, Il-6, Il-10), chemokine (Ccl2, Ccl3, Ccl5, ...
Ref: cord_uid xrcvyu87 Immune environment modulation in pneumonia pat... xrcvyu87 Immune environment modulation in pneumonia pat... Name: title, dtype: object [J. immunotherap. cancer, cord_uid xrcvyu87 2020 xrcvyu87 2020 Name: publish_time, dtype: object]interleukin (IL)-1 β, IL-6, tumor necrosis factor (TNF), and chemokines by respiratory epithelial and dendritic cells, and macrophages
... This storm is due to the release of high levels of pro-inflammatory cytokines such as interleukin (IL)-1 β, IL-6, tumor necrosis factor (TNF), and chemokines by respiratory epithelial and dendritic cells, and macrophages We hypothesize that this cytokine storm and the worsening of patients’ health status can be ...
Ref: Targeting the cholinergic anti-inflammatory pathway with vagus nerve stimulation in patients with Covid-19? [Bioelectronic Medicine, 2020]All of the data sets showed significant enrichment for signaling mediated by interleukin-4, -10 and -13 ( Table 6 ).
... GS398329, preselected to be associated with angiogenesis, also showed significant enrichment for the comorbidity pathways associated with platelet biology. All of the data sets showed significant enrichment for signaling mediated by interleukin-4, -10 and -13 ( Table 6 ). ...
Ref: Investigation of COVID-19 comorbidities reveals genes and pathways coincident with the SARS-CoV-2 viral disease. [bioRxiv, 2020-09-21]IL-17 inhibitors were presented as promising targets for the prevention of aberrant inflammation and acute respiratory distress in COVID-19.
... them experienced severe COVID-19. Interleukin-17 has been related to the hyperinflammatory state in COVID-19 and IL-17 inhibitors were presented as promising targets for the prevention of aberrant inflammation and acute respiratory distress in COVID-19. However, this hypothesis still remains to be proved. Further studies are warranted in order to ...
Ref: cord_uid 1fea6mgk Coronavirus disease 2019 (COVID-19) in a patie... 1fea6mgk Coronavirus disease 2019 (COVID-19) in a patie... Name: title, dtype: object [bioRxiv, cord_uid 1fea6mgk 2020 1fea6mgk 2020 Name: publish_time, dtype: object]IL-1β, IL-7, IL-8, IL-9 level increase in initial plasma concentration [3] .
... In COVID-19, patient CT lung scan with multiple bilateral lobular pneumonia is associated with IL-1β, IL-7, IL-8, IL-9 level increase in initial plasma concentration [3] . These cytokines are released from damaged tissue and are early immune drivers of the immune response ...
Ref: Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines [Open Biol, 2020-09-23]interleukin (IL)-6, IL-1ß, and tumor necrosis factor (TNF)-α.
... worsening respiratory symptoms, persistent fever, and hemodynamic instability. Important cytokines involved in this phase are interleukin (IL)-6, IL-1ß, and tumor necrosis factor (TNF)-α. This is typically followed by a recovery phase with production of antibodies against the virus. ...
Ref: Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents [Virol J, 2020]Excessive interleukin-6 signaling is a key factor contributing to the cytokine release syndrome implicated in clinical manifestations of COVID-19.
... Excessive interleukin-6 signaling is a key factor contributing to the cytokine release syndrome implicated in clinical manifestations of COVID-19. Preliminary results suggest that tocilizumab, a humanized monoclonal anti-interleukin-6 receptor antibody, may be beneficial in severely ill patients, but no data are available on earlier stages of disease. An anticipated ...
Ref: Preemptive interleukin-6 blockade in patients with COVID-19 [Sci Rep, 2020]interleukin-6 (IL-6) and tumoral necrosis factor-alpha (TNF-α),
... found in these cardiometabolic comorbidities is marked by the overexpression of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumoral necrosis factor-alpha (TNF-α), which are products of the Toll-Like receptors 4 (TLR4) pathway. The SARS-CoV-2 initially infects cells ...
Ref: Is Toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities? [Cytokine growth factor rev, 2020]Interleukin-6 (IL-6) has emerged as a key component of the immune response to SARS-CoV-2,
... in the field of infectious disease, but it also has particular relevance to cancer research. Interleukin-6 (IL-6) has emerged as a key component of the immune response to SARS-CoV-2, such that the repurposing of anti-IL-6 therapeutics for COVID-19 is now a major line of ...
Ref: Cytokine Storms in Cancer and COVID-19 [Cancer cell, 2020]Tocilizumab is a blocker of IL-6R that can effectively block IL-6 signal transduction pathway.
... anakinra, neutralizes the activity that pertains to these key mediators of autoinflammatory and/or immune processes. Tocilizumab is a blocker of IL-6R that can effectively block IL-6 signal transduction pathway. Omalizumab that binds to the CH3 domain, is near to the binding site for the ...
Ref: Future Perspective: Biologic agents in patients with Severe Covid-19. [Immunopharmacology and immunotoxicology, 2020-09-04]Interferon-γ and IL-17 are involved in inducing and mediating proinflammatory responses.
... COVID‐19. Th1 (IFN-γ), Treg (TGF-β), and Th17 (IL-17) cytokines concentration were increased in COVID-19 patients. Interferon-γ and IL-17 are involved in inducing and mediating proinflammatory responses. Our data suggest that TGF-β can be used as a predictive factor of disease severity ...
Ref: Cytokine Profile and Disease Severity in Patients with COVID-19 [Cytokine, 2020-09-30]TNF, IFN-γ, IL-6, CRP, EGFR, CCL5, IL-10, TGFβ1, and other genes.
... be involved in the ARDS and cytokine storms. PDL may attenuate cytokine storms by affecting TNF, IFN-γ, IL-6, CRP, EGFR, CCL5, IL-10, TGFβ1, and other genes. These genes may be the hub genes involved in the effects of PDL, LHQW, and ...
Ref: Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools [Biomed Pharmacother, 2020-05-30]interleukin-4, interleukin -13, interleukin -17 signaling, and TNF signaling pathways.
... revealed the DEGs were found in influenza A, measles, cytokine signaling in the immune system, interleukin-4, interleukin -13, interleukin -17 signaling, and TNF signaling pathways. Protein-protein interaction analysis showed 10 hub genes (BIRC3, ICAM1, IRAK2, MAP3K8, S100A8, SOCS3, STAT5A, TNF, ...
Ref: Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19 [Eur J Pharmacol, 2020]interleukin-6 antagonists
... a so-called cytokine storm in patients with COVID-19 has prompted consideration of anti-cytokine therapies, particularly interleukin-6 antagonists However, direct systematic comparisons of COVID-19 with other critical illnesses associated with elevated cytokine concentrations ...
Ref: Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes [The Lancet Respiratory Medicine, 2020]interleukin 6 (IL-6), interferons, and CXCL10 (IP-10).
... macrophages, both direct and indirect, and potential therapeutic targets. These include granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 6 (IL-6), interferons, and CXCL10 (IP-10). Various biopharmaceuticals are being repurposed to target the cytokine storm in COVID-19 patients. In addition, ...
Ref: Macrophage responses associated with COVID-19: A pharmacological perspective [Eur J Pharmacol, 2020-09-11]IL-6, IL-1α/β, IL-12, IL-17, IFN-γ, TNF-α (130) .
... r o o f Observed data emphasize heterogenecity of cytokine storm immunopathology mechanism in COVID-19. Therefore, GC maybe uniqluy positioned in antiinflammatory control due to inhibiting broader range of cytokines IL-6, IL-1α/β, IL-12, IL-17, IFN-γ, TNF-α (130) . ...
Ref: The role of Interleukin 6 inhibitors in therapy of severe COVID-19 [Biomed Pharmacother, 2020-08-28]interleukin-2 receptor, interleukin-6, interleukin-8, and tumor necrosis factor-α
... T cells, CD8+ T cells, and NK cells and remarkably higher concentrations of cytokines including interleukin-2 receptor, interleukin-6, interleukin-8, and tumor necrosis factor-α on admission compared with the survived subjects. A model based on the combination of interleukin-8 ...
Ref: Prediction Model Based on the Combination of Cytokines and Lymphocyte Subsets for Prognosis of SARS-CoV-2 Infection [J Clin Immunol, 2020]interleukin (IL)-17A, and biomarkers associated with arterial damage.
... with Kawasaki disease, but also differs from this condition with respect to T cell subsets, interleukin (IL)-17A, and biomarkers associated with arterial damage. Finally, autoantibody profiling suggests multiple autoantibodies that could be involved in the pathogenesis of MIS-C. ...
Ref: The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19 [Cell, 2020]Tocilizumab (TCZ), an interleukin-6 (IL-6) inhibitor,
... with coronavirus disease 2019 (COVID-19) is life-threatening and can occur very rapidly after COVID-19 diagnosis. Tocilizumab (TCZ), an interleukin-6 (IL-6) inhibitor, may ameliorate the CRS associated with severe COVID-19 and thus improve clinical outcomes. We present ...
Ref: Effectiveness of tocilizumab in a COVID-19 patient with cytokine release syndrome [Eur. J. Case Rep. Intern. Med., 2020]Pro-inflammatory cytokines such as TNF-α and IL-6 induce tissue factor expression in monocytes and initiate coagulation cascade activation.
... Regardless of its clinical impact, coagulopathy seems to be triggered by hypercytokinemia [133] . Pro-inflammatory cytokines such as TNF-α and IL-6 induce tissue factor expression in monocytes and initiate coagulation cascade activation. In addition, these cytokines also suppress endogenous anticoagulant pathways [131] . MAS-like can cause local activation ...
Ref: Severe COVID-19: what have we learned with the immunopathogenesis? [Adv Rheumatol, 2020-09-22]Interleukin-6 plays an important role in cytokine storm.
... world. COVID-19 is currently a global pandemic. There are cytokine storms in severe COVID-19 patients. Interleukin-6 plays an important role in cytokine storm. Tocilizumab is a blocker of interleukin-6 receptor, which is likely to become an effective drug ...
Ref: cord_uid vgxnkfgz Tocilizumab in the treatment of a critical COV... vgxnkfgz Tocilizumab in the treatment of a critical COV... Name: title, dtype: object [Adv Rheumatol, cord_uid vgxnkfgz 2020 vgxnkfgz 2020 Name: publish_time, dtype: object]recombinant soluble glycoprotein 130 and recombinant ADAM17/TACE prodomain inhibitor.
... may be restored by recovering an IL-6 trans-signaling neutralizing buffer system through the mediation of recombinant soluble glycoprotein 130 and recombinant ADAM17/TACE prodomain inhibitor. This cytokine restoration, possibly combined with inhibition of SARS-CoV-2 entry as well as replication and ...
Ref: A combinational approach to restore cytokine balance and to inhibit virus growth may promote patient recovery in severe COVID-19 cases [Cytokine, 2020]interleukin-6 (IL-6) and other cytokines/chemokines play a pivotal pro-inflammatory role.
... well as to lung infiltration sustained by neutrophils and macrophages. Within such a pathogenic context, interleukin-6 (IL-6) and other cytokines/chemokines play a pivotal pro-inflammatory role. Therefore, cytokines and their receptors, as well as cytokine-dependent intracellular signalling pathways can be targeted ...
Ref: Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications [Ther Adv Respir Dis, 2020]IL-6 inhibitors such as tocilizumab are expected to be effective for its treatment.
... interleukin-6 (IL-6) is considered to be associated with severe cases of Coronavirus disease 2019 (COVID-19), IL-6 inhibitors such as tocilizumab are expected to be effective for its treatment. METHODS This was a retrospective study using a consecutive cohort of 224 patients hospitalized with ...
Ref: The Association of Interleukin-6 value, Interleukin inhibitors and Outcomes of Patients with COVID-19 in New York City. [Journal of medical virology, 2020-07-28]Roxolitinib is an inhibitor of JAK ½ and is associated with multiple cellular signals including IL-6.
... Roxolitinib is an inhibitor of JAK ½ and is associated with multiple cellular signals including IL-6. The study intended to stop the dysregulated immune response caused by COVID-19. This drug work as an immunomodulator decreasing the respiratory or pneumonia symptoms caused by dysregulated immune response. It ...
Ref: COVID19 inhibitors: A prospective therapeutics [Bioorg Chem, 2020-06-17]Interleukin 6 (IL-6) took center stage as a therapeutic target, given its role in the cytokine storm phase of COVID-19.
... Interleukin 6 (IL-6) took center stage as a therapeutic target, given its role in the cytokine storm phase of COVID-19. While IL-6 inhibitors have been widely used to treat a variety of immune-mediated disease states, they have not been used often in the intensive care setting, and new data question ...
Ref: cord_uid 373l9wcy Practical aspects of targeting IL-6 in COVID-1... 373l9wcy Practical aspects of targeting IL-6 in COVID-1... Name: title, dtype: object [Bioorg Chem, cord_uid 373l9wcy 2020 373l9wcy 2020 Name: publish_time, dtype: object]Massive cytokines including interleukin-6, nuclear factor kappa B (NFκB), and tumor necrosis factor alpha (TNFα)
... high mortality that may be closely related to the hyper-proinflammatory status called the “cytokine storm.” Massive cytokines including interleukin-6, nuclear factor kappa B (NFκB), and tumor necrosis factor alpha (TNFα) released from SARS-CoV-2-infected macrophages and monocytes lead inflammation-derived injurious cascades causing multi-organ injury/failure. This review ...
Ref: Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications [Inflammation, 2020-10-08]Interleukin (IL)-6 is one of the most important proinflammatory cytokines [58] .
... may not be primarily due to SARS-CoV-2 per se but the cytokine storm [58] . Interleukin (IL)-6 is one of the most important proinflammatory cytokines [58] . Hence, specific blockade of the IL-6-regulated signaling pathways represents a promising approach to attenuate inflammation-associated ...
Ref: A Double-Edged Sword—Cardiovascular Concerns of Potential Anti-COVID-19 Drugs [Cardiovasc Drugs Ther, 2020-06-17]interleukin-6 pathway inhibitors,
... role of various cytokines in the pathophysiology of COVID-19 Targeting the inflammatory mediators in the pathogenesis, especially interleukin-6 pathway inhibitors, would improve overall morbidity and mortality, thus decreasing the burden on healthcare systems ...
Ref: The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series [Cureus, 2020]interleukin IL-1 family members and secondary cytokines like IL-6.
... the later phase of the disease appears to be driven by a cytokine storm, including interleukin IL-1 family members and secondary cytokines like IL-6. IL-18 may participate in this hyperinflammation, as it was previously found to be able to ...
Ref: IL-18 and infections: Is there a role for targeted therapies? [Journal of cellular physiology, 2020-08-13]C-reactive protein (CRP) and interleukin-6 (IL-6) levels significantly decreased during treatment.
... had a fatal outcome due to nosocomial infections. The five seriously ill patients considerably improved. C-reactive protein (CRP) and interleukin-6 (IL-6) levels significantly decreased during treatment. CIGB-258 seems to be an effective and safe treatment option in COVID-19 patients under cytokine ...
Ref: CIGB-258 immunomodulatory peptide: a novel promising treatment for critical and severe COVID-19 patients [Journal of cellular physiology, 2020-06-02]PDL might prevent the entrance of SARS-CoV-2 entry into cells by blocking the angiotensin-converting enzyme 2 (ACE2).
... for PDL treatment on COVID-19 was validated by the TCMATCOV (TCM Anti COVID-19) platform. RESULTS: PDL might prevent the entrance of SARS-CoV-2 entry into cells by blocking the angiotensin-converting enzyme 2 (ACE2). It might inhibit the cytokine storm by affecting C-reactive protein (CRP), interferon-γ (IFN-γ), interleukin- 6 ...
Ref: Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools [Biomed Pharmacother, 2020]interleukin-1 (IL-1), IL-6, CCL2 protein, and CXCL10 protein.
... increased levels of a variety of T-helper 1 (Th1) and inflammatory cytokines and chemokines, including interleukin-1 (IL-1), IL-6, CCL2 protein, and CXCL10 protein. In the absence of proven antiviral agents or an effective vaccine, substances with immunomodulatory activity ...
Ref: Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity? [MSphere, 2020]IL-6, interleukin 6; CRP, C-reactive protein; PCT, procalcitonin.
... factors to predict disease risk. However, the validity of PCT needs to be further investigated. IL-6, interleukin 6; CRP, C-reactive protein; PCT, procalcitonin. Data are presented as median (IQR), n (%), or n/N (%). P-values were calculated using ...
Ref: Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 [Journal of Clinical Virology, 2020-06-30]IL-1α and IL-1β are responsible for direct and indirect host response.
... with other cytokine families, are more associated with nonspecific, damaging inflammation [79] . Of these, IL-1α and IL-1β are responsible for direct and indirect host response. In addition, IL-1β is detectable in bronchoalveolar lavage fluid in patients with ARDS [80] . ...
Ref: Countermeasures to COVID-19: Are immunomodulators rational treatment options — a critical review of the evidence [Open Forum Infect Dis, 2020-06-05]Interleukin (IL)-17 is one of the pro-inflammatory mediators secreted in coronavirus infection [9] .
... Our understanding about the immunological pathways in COVID-19 is improving rapidly. Interleukin (IL)-17 is one of the pro-inflammatory mediators secreted in coronavirus infection [9] . Knowledge on the course of SARS-CoV-2 infection among patients receiving IL-17 inhibitors is increasing. The aims of the present ...
Ref: Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review [Rheumatol Int, 2020-06-26]Inflammatory cytokines such as interleukin-6 (IL-6) cause acute liver injury while serum detectability indicates systemic inflammation.
... BACKGROUND: A cytokine storm conceivably contributes to manifestations of corona virus disease (COVID-19). Inflammatory cytokines such as interleukin-6 (IL-6) cause acute liver injury while serum detectability indicates systemic inflammation. AIMS: We explored a link between systemic IL-6, related acute phase proteins and liver injury in hospitalized ...
Ref: Systemic inflammation as fuel for acute liver injury in COVID-19 [Dig. liver dis, 2020]Specific immune modulators include anti-cytokines such as interleukin (IL)-1 and IL-6 receptor antagonists
... terms "coronavirus", "immunology", "cytokine storm", "immunomodulators", "pharmacology", "severe acute respiratory syndrome 2", "SARS-CoV-2", and "COVID-19". Specific immune modulators include anti-cytokines such as interleukin (IL)-1 and IL-6 receptor antagonists (e.g. anakinra, tocilizumab, sarilumab, siltuximab), Janus kinase (JAK) inhibitors (e.g. baricitinib, ruxolitinib), anti-tumor necrosis factor-α ...
Ref: Pharmaco-Immunomodulatory Therapy in COVID-19 [Drugs, 2020]TNF-α and IL-17A stimulate the synthesis of IL-8 by the respiratory epithelium;
... TNF-α and IL-17A stimulate the synthesis of IL-8 by the respiratory epithelium; this interleukin is a potent chemotactic of neutrophils in the lung [31] . Neutrophilia in the respiratory epithelium is associated with severity and death in respiratory diseases such as asthma ...
Ref: IL-17A and TNF-α as potential biomarkers for acute respiratory distress syndrome and mortality in patients with obesity and COVID-19 [Med Hypotheses, 2020-08-07]Interleukin-6 (IL-6), IL-10 and C-reactive protein
... The number of immunosuppressive regulatory T cells was moderately increased in patients with mild COVID-19. Interleukin-6 (IL-6), IL-10 and C-reactive protein were remarkably up-regulated in patients with severe COVID-19. In conclusion, our study shows that the ...
Ref: Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China [Immunology, 2020]IL-1β, IL-6, IL-10 and tumor necrosis factor alpha (Figure 2) .
... established biologic efficacy. We therefore conducted a preliminary evaluation of tocilizumab on inflammatory cytokines including IL-1β, IL-6, IL-10 and tumor necrosis factor alpha (Figure 2) . Further, mean arterial pressure improved following tocilizumab on days 3 (P=0.042), 4 (P=0.042) and 6 ...
Ref: Amelioration of COVID‐19 related cytokine storm syndrome: Parallels to chimeric antigen receptor‐T cell cytokine release syndrome [Br J Haematol, 2020-06-25]Anakinra is a human IL-1 receptor antagonist.
... called cytokine storm) on endothelium level, then it may cause severe coronavirus disease 2019 (COVID-19). Anakinra is a human IL-1 receptor antagonist. By inhibiting IL-1α/IL-1β competitively from binding to the IL-1 type-I receptor, anakinra, neutralizes the activity ...
Ref: Future Perspective: Biologic agents in patients with Severe Covid-19. [Immunopharmacology and immunotoxicology, 2020-09-04]IL-1β, IL-6, IL-12, tumour necrosis factor and interferon γ.
... with a cytokine storm, which is characterised by increased plasma concentrations of the proinflammatory cytokines IL-1β, IL-6, IL-12, tumour necrosis factor and interferon γ. 3 It produces a cytokine release syndrome, with a pattern similar to that of secondary ...
Ref: Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19 [Eur J Hosp Pharm, 2020-06-04]interleukin-1, -6, and TNF inhibitors, as well as less targeted therapies, such as corticosteroids, chloroquine, or JAK inhibitors.
... in severe COVID-19 (i.e. interleukin-1ß-driven macrophage activation syndrome vs. interleukin-6-driven immune dysregulation). Next, reviewing current evidence drawn from clinical trials, we examine a number of cytokine and anti-cytokine therapies, including interleukin-1, -6, and TNF inhibitors, as well as less targeted therapies, such as corticosteroids, chloroquine, or JAK inhibitors. ...
Ref: Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions [Autoimmun Rev, 2020]interleukin (IL) -6, IL-10 and TNF-α.
... these circumstances, persistent viral stimulation leads to a significant increase in circulating cytokines such as interleukin (IL) -6, IL-10 and TNF-α. We describe a clinical series of eight patients treated with Sarilumab an IL-6R inhibitor administered ...
Ref: COVID‐19 pneumonia treated with Sarilumab: A clinical series of eight patients [J Med Virol, 2020-06-16]interleukin (IL)-1ß and IL-6.
... can cause mild or highly acute respiratory syndrome with consequent release of pro-inflammatory cytokines, including interleukin (IL)-1ß and IL-6. The binding of COVI-19 to the Toll Like Receptor (TLR) causes the release of pro-IL-1ß ...
Ref: cord_uid 3d0olw0t Induction of pro-inflammatory cytokines (IL-1 ... 3d0olw0t Induction of pro-inflammatory cytokines (IL-1 ... Name: title, dtype: object [J Med Virol, cord_uid 3d0olw0t 2020 3d0olw0t 2020 Name: publish_time, dtype: object]interleukin-6 (IL-6) is an important component of the COVID-19 cytokine storm As a specific antagonist of IL-6,
... pathophysiological basis of coronavirus disease 2019 (COVID-19) causing respiratory failure is a cytokine storm and interleukin-6 (IL-6) is an important component of the COVID-19 cytokine storm As a specific antagonist of IL-6, tocilizumab may block the cytokine storm of COVID-19 The Diagnosis and Treatment Guidelines of New ...
Ref: Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients [World J Clin Cases, 2020]Treatment with tocilizumab, a monoclonal antibody directed against the interleukin-6 (IL-6) receptor,
... BACKGROUND: Evidence links COVID-19 severity to hyper-inflammation. Treatment with tocilizumab, a monoclonal antibody directed against the interleukin-6 (IL-6) receptor, was shown to lead to clinical improvement in patients with severe COVID-19. We, therefore, performed the present systematic review and meta-analysis to investigate ...
Ref: Interleukin-6 and severe COVID-19: a systematic review and meta-analysis [Eur Cytokine Netw, 2020]IL-1β, IL-6, TNFα, IFNγ.
... storm: Beta-adrenergic blockers have been shown to decrease a variety of proinflammatory cytokines expression including IL-1β, IL-6, TNFα, IFNγ. [52] [53] [54] [55] [56] The use of beta-adrenergic blockers in COVID-19 patients may reduce ...
Ref: Beta‐adrenergic Blockers as a Potential Treatment for COVID‐19 Patients [Bioessays, 2020-08-20]Interleukin (IL)-6, IL-10, and tumor necrosis factor (TNF)-α surge during illness and decline upon recovery;
... serum levels of multiple cytokines [3] , probably produced by highly inflammatory macrophages [8] . Interleukin (IL)-6, IL-10, and tumor necrosis factor (TNF)-α surge during illness and decline upon recovery; overproduction of IL-6, IL-10, soluble IL-2 receptor, and TNFα is inversely correlated with CD4+ and ...
Ref: Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic [Am J Clin Dermatol, 2020-04-10]interleukins (IL-1, IL-6, etc.), and TNF-α.
... rate (Hypoxia), hear rate, fever,irregular neutrophil counts (neutropenia), and higher level of plasma cytokines i.e. interleukins (IL-1, IL-6, etc.), and TNF-α. All these symptoms are the reason to promote disease severity. SARS-CoV-2 virus detected in both ...
Ref: Novel β-Coronavirus (SARS-CoV-2): Current and Future Aspects of Pharmacological Treatments [Saudi Pharm J, 2020-08-27]IL2, IL7, G-CSF, IP-10, MCP-1, MIP-1a, and TNF-a,
... of infection to the late stage of infection. In particular, increased release of cytokines, including IL2, IL7, G-CSF, IP-10, MCP-1, MIP-1a, and TNF-a, is present in patients with severe COVID-19 [26] . Moreover, extreme cases of COVID-19 surge ...
Ref: Interleukin-6 and severe COVID-19: a systematic review and meta-analysis [Eur Cytokine Netw, 2020-10-02]interleukin 17 (IL-17), interleukin 8 (IL-8) and interleukin 6 (IL-6).
... and hypoxia is marked elevation of serum cytokines, especially interferon gamma, tumor necrosis factor alpha, interleukin 17 (IL-17), interleukin 8 (IL-8) and interleukin 6 (IL-6). Initial experience from the outbreaks in Italy, China and the USA has anecdotally demonstrated improved ...
Ref: cord_uid 5f63n7ex The Society for Immunotherapy of Cancer perspe... 5f63n7ex The Society for Immunotherapy of Cancer perspe... Name: title, dtype: object [Eur Cytokine Netw, cord_uid 5f63n7ex 2020 5f63n7ex 2020 Name: publish_time, dtype: object]interleukin-1β, interleukin-6, interleukin-10, and tumor necrosis factor-α
... physiologic, and laboratory data were collected daily Daily serum samples were drawn for measurements of interleukin-1β, interleukin-6, interleukin-10, and tumor necrosis factor-α Pulmonary outcomes were the ratio of Pao(2)/Fio(2) and static lung compliance Twenty-six patients with coronavirus ...
Ref: The Association of Inflammatory Cytokines in the Pulmonary Pathophysiology of Respiratory Failure in Critically Ill Patients With Coronavirus Disease 2019 [Crit Care Explor, 2020]Interleukin 6 is involved in the cytokine cascade,
... immune response to the disease, and in ClinicalTrials.gov on clinical trials with interleukin 6 blockers. Interleukin 6 is involved in the cytokine cascade, which originates as a consequence of an excessive immune response secondary to viral infection, aggravating ...
Ref: cord_uid 1b1hk9nf Involvement of interleukin 6 in SARS-CoV-2 inf... 1b1hk9nf Involvement of interleukin 6 in SARS-CoV-2 inf... Name: title, dtype: object [Crit Care Explor, cord_uid 1b1hk9nf 2020 1b1hk9nf 2020 Name: publish_time, dtype: object]protease inhibitors, hydroxychloroquine/chloroquine, or interleukin (IL)-1/IL-6 receptor antagonists.
... therapeutic drug monitoring of CNIs/mTOR inhibitors and appropriate dose reduction is recommended in co-administration with protease inhibitors, hydroxychloroquine/chloroquine, or interleukin (IL)-1/IL-6 receptor antagonists. Complete blood count monitoring is recommended in patients who continue taking antimetabolites or mTOR inhibitors. ...
Ref: Pharmacotherapeutic considerations in solid organ transplant patients with COVID-19. [Expert opinion on pharmacotherapy, 2020-07-13]the activation of Tregulatory cells, and the inhibition of proinflammatory cytokine production such as interleukin-6, tumor necrosis factor-α and interferon-γ .
... endosomal innate immune sensor capable of detecting single-stranded RNA), the modulation of complement-dependent antigen/antibody reactions, the activation of Tregulatory cells, and the inhibition of proinflammatory cytokine production such as interleukin-6, tumor necrosis factor-α and interferon-γ . 12 Therefore, hydroxychloroquine immediately appeared attractive to attenuate the inflammatory response directed against SARS-CoV-2 that ...
Ref: Hydroxychloroquine and Azithromycin to Treat Patients With COVID‐19: Both Friends and Foes? [J Clin Pharmacol, 2020-05-20]Serum cytokines including IL-1β, IL-2R, IL-6, IL-8, IL-10, and TNFα
... Blood samples were collected from the patients on admission or the second day after admission. Serum cytokines including IL-1β, IL-2R, IL-6, IL-8, IL-10, and TNFα were measured using chemiluminescent immunoassay (CLIA) by Siemens Immulite 1000 analyzer according to the manufacturer"s ...
Ref: Association between cytokine profiles and lung injury in COVID-19 pneumonia [Respir Res, 2020-07-29]interleukin‐6 receptor antagonist (IL‐6Ra) tocilizumab.
... that is evolving rapidly at present with unprecedented global health and societal implications. Herein, we report a case of successful treatment of SARS‐CoV‐2 induced inflammatory syndrome by utilization of the interleukin‐6 receptor antagonist (IL‐6Ra) tocilizumab. ...
Ref: Interleukin‐6 Receptor Antagonist Therapy to Treat SARS‐CoV‐2 Driven Inflammatory Syndrome in a Renal Transplant Recipient [Transpl Infect Dis, 2020-05-14]Tocilizumab is a blocker of IL-6R, which can effectively block IL-6 signal transduction pathway.
... of IL-6, it is expected to become a new method for the treatment of severe patients. Tocilizumab is a blocker of IL-6R, which can effectively block IL-6 signal transduction pathway. So, tocilizumab is likely to become an effective drug for patients with severe COVID-19. ...
Ref: The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality [Int J Antimicrob Agents, 2020-03-29]IL-6, IL-1 and TNFα pathways.
... block or modulate the systemic inflammatory response and pulmonary complications caused by COVID-19, in particular, IL-6, IL-1 and TNFα pathways. 15 ratIonale for targetIng Il-6 SARS-CoV-2 causes the emergent respiratory disease called COVID-19. One of ...
Ref: The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response [J Immunother Cancer, 2020-05-07]interleukin 1β (IL-1β), IL-6, and tumor necrosis factor α (TNF- α) through different routes.
... in the patients who have received antibiotics with inflammatory properties which mainly is release of interleukin 1β (IL-1β), IL-6, and tumor necrosis factor α (TNF- α) through different routes. Altogether, we highly recommend clinicians to look after those antibiotics with anti-inflammatory activity for both ...
Ref: Inappropriate Antibiotic Consumption as a Possible Cause of Inflammatory Storm and Septic Shock in Patients Diagnosed with Coronavirus-19 Disease (COVID-19) [Arch Med Res, 2020-04-04]inhibiting T1IFN pathways and thwarting the 'correct' and relevant Th1 pathway.
... be favored if the virus could force the immune system towards this incorrect response by inhibiting T1IFN pathways and thwarting the "correct" and relevant Th1 pathway. Therefore, what is being referred to as a cytokine storm may really be more of ...
Ref: The cytokine storm – An appropriate, over‐reactive response to SARS‐COV‐2 or the wrong immune pathway? [Scand J Immunol, 2020-09-29]interleukin-6 (IL6).
... destruction appears to be associated with a cytokine storm related to an increased level of interleukin-6 (IL6). Therapeutic targeting of the interleukin-6 signaling pathway can attenuate such a cytokine storm and can ...
Ref: cord_uid bn8qjliy Role of Interleukin-6 in Lung Complications in... bn8qjliy Role of Interleukin-6 in Lung Complications in... Name: title, dtype: object [Scand J Immunol, cord_uid bn8qjliy 2020 bn8qjliy 2020 Name: publish_time, dtype: object]Interleukin-6 (IL-6) orchestrates the so-called cytokine storm leading to the Acute Respiratory Distress Syndrome (ARDS),
... That paradox has important practical implications for the use of the drug Tocilizumab in Covid-19 Interleukin-6 (IL-6) orchestrates the so-called cytokine storm leading to the Acute Respiratory Distress Syndrome (ARDS), the life-threatening condition that is responsible for Covid-19 deaths However, IL-6 has a paradoxical effect ...
Ref: The paradoxical effect of IL-6 and implications for the use of Tocilizumab in Covid-19 patients [Medical Hypotheses, 2020]The inflammatory cytokine interleukin-6 (IL-6) is pivotal for orchestrating the immune response.
... The inflammatory cytokine interleukin-6 (IL-6) is pivotal for orchestrating the immune response. Inhibitors of IL-6 signaling are being investigated as treatments for severe coronavirus disease 2019 (COVID-19). We conducted a Mendelian randomization study investigating the effect of IL-6 signaling on susceptibility to ...
Ref: Genetically proxied inhibition of interleukin-6 signaling: opposing associations with susceptibility to COVID-19 and pneumonia [Medical Hypotheses, 2020-09-18]interleukin 6 (IL-6) and tumour necrosis factor-alpha (TNF-).
... SARS, which can be due in part to the increase of proinflammatory cytokines such as interleukin 6 (IL-6) and tumour necrosis factor-alpha (TNF-). CLQ is highly effective in combination with remdesivir in controlling SARS-CoV-2 8 in vitro. There ...
Ref: Therapeutic Options for the Management of Severe COVID-19: A Rheumatology Perspective [Medical Hypotheses, 2020-10-15]interleukin-4, interleukin −13, interleukin −17 signaling, and TNF signaling pathways.
... revealed the DEGs were found in influenza A, measles, cytokine signaling in the immune system, interleukin-4, interleukin −13, interleukin −17 signaling, and TNF signaling pathways. Protein-protein interaction analysis showed 10 hub genes (BIRC3, ICAM1, IRAK2, MAP3K8, S100A8, SOCS3, STAT5A, TNF, ...
Ref: Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19 [Eur J Pharmacol, 2020-09-22]IL-1 and IL-6 inhibitors, glucocorticoids, convalescent plasma, among others).
... entry (remdesivir, umifenovir, among others) and blocking of immune system for cytokine storm control ( IL-1 and IL-6 inhibitors, glucocorticoids, convalescent plasma, among others). CONCLUSIONS: Understanding of action mechanisms of SARS-CoV-2 enables us to direct efforts on effective therapeutic ...
Ref: Review on therapeutic targets for COVID-19: insights from cytokine storm [Postgrad. med. j, 2020]PARPi can effectively decrease IL-6, IL-1 and TNF-α
... 2 (SARS-CoV-2) and combat the life-threatening sequelae of coronavirus disease 2019 (COVID-19) by several mechanisms. PARPi can effectively decrease IL-6, IL-1 and TNF-α levels (key interleukins in SARS-CoV-2-induced cytokine storm) and can alleviate subsequent lung fibrosis, as demonstrated ...
Ref: Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome? [Br J Pharmacol, 2020]antibodies against IL-1, the IL-6 receptor, granulocyte-macrophage colonystimulating factor as well as inhibitors of Janus-kinase
... order to mitigate an excessive host response and thereby reduce organ damage. In this context, antibodies against IL-1, the IL-6 receptor, granulocyte-macrophage colonystimulating factor as well as inhibitors of Janus-kinase are currently evaluated for treating hyperinflammation in COVID-19. Substantial experience exists with those agents in ...
Ref: Extracorporeal Hemoadsorption: An Option for COVID-19 Associated Cytokine Storm Syndrome [Shock, 2020-05-18]We propose to utilize interleukin-6 (IL-6) blockade to manage COVID-19-induced CRS
... that in SARS and Middle East respiratory syndrome (MERS), and summarize the existing therapies for CRS. We propose to utilize interleukin-6 (IL-6) blockade to manage COVID-19-induced CRS and discuss several factors that should be taken into consideration for its clinical application. ...
Ref: Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? [J Autoimmun, 2020]IL-1 beta (ß), IL-8, and tumor necrosis factor-alpha (TNF-α),
... of immune responses to the mentioned viruses. IL-6, along with some other inflammatory cytokines, including IL-1 beta (ß), IL-8, and tumor necrosis factor-alpha (TNF-α), as well as inflammatory chemokines, can significantly contribute to, fever, lymphopenia, coagulation, lung injury, and ...
Ref: The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics [Life Sci, 2020]tumor necrosis factor (TNF)-α, interleukin (IL)-6, interferon (IFN)-γ, and IL-10,
... distress syndrome caused by hyper inflammation secondary to cytokine release syndrome (CRS). Cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, interferon (IFN)-γ, and IL-10, are the main mediators of CRS. Based on recent evidence, the angiotensin-converting enzyme (ACE) II ...
Ref: Angiotensin-Converting Enzyme as a new immunologic target for the new SARS-CoV-2. [Immunology and cell biology, 2020-08-30]tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and IL-1β with different pro-inflammatory roles.
... trigger life-threatening cytokine release syndrome (CRS) which can result in overproduction of pro-inflammatory cytokines including tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and IL-1β with different pro-inflammatory roles. Anecdotal evidence suggests that the modulation of systemic immune responses may have a potential role ...
Ref: Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review [Arch Med Res, 2020-06-19]interleukin-6 receptor (IL) inhibitors (IL-6R), IL-1 inhibitors, or JAK kinase inhibitors.
... some of these treatments are being investigated as potential therapies for the disease, including antimalarials, interleukin-6 receptor (IL) inhibitors (IL-6R), IL-1 inhibitors, or JAK kinase inhibitors. Confirmed data show that a subgroup of infected patients initially develop a phase of viral ...
Ref: COVID-19: overview of rheumatology fellows [Arch Med Res, 2020-10-15]interleukin 4 (IL-4), interleukin 10 (IL-10), and interferon γ.
... particularly neutrophils and monocytes. E2 stimulates CD4+ T-helper cell production of anti-inflammatory cytokines, for example, interleukin 4 (IL-4), interleukin 10 (IL-10), and interferon γ. Generally, high E2 concentrations favor helper T-cell type 2 (Th2)-type anti-inflammatory responses. E2 decreases interleukin ...
Ref: Estradiol, Progesterone, Immunomodulation, and COVID-19 Outcomes [Endocrinology, 2020-07-30]IL-6, IL-1b and TNF
... during COVID-19, mainly by antigen presenting dendritic cells, which produce large amounts of cytokines, including IL-6, IL-1b and TNF and migrate to the regional lymph nodes to present viral antigen to naïve T cells, ...
Ref: IL-6: relevance for immunopathology of SARS-CoV-2 [Cytokine Growth Factor Rev, 2020-05-20]Interleukin 6 (IL-6) inhibitor (tocilizumab)
... The world is in the midst of the coronavirus disease 2019 (COVID-19) pandemic. Interleukin 6 (IL-6) inhibitor (tocilizumab) had been suggested for the treatment of acute respiratory distress syndrome (ARDS) patients based on the concept ...
Ref: Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far? [Drug Discov Ther, 2020]Anti-IL-6 and anti-IL-6R agents inhibit sIL-6R and mIL-6R-mediated signaling.
... the treatment, while a constant increase was observed for four patients for whom [62] . Anti-IL-6 and anti-IL-6R agents inhibit sIL-6R and mIL-6R-mediated signaling. IL-6 interleukin 6, IL-6R interleukin 6 receptor, JAK Janus kinase, SARS-CoV-2 severe acute respiratory syndrome ...
Ref: Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks [BioDrugs, 2020-06-15]Interleukin (IL)-17, IL-12/23, and IL-23 inhibitors are associated with low infection risk,
... until there is more data; in uninfected patients switching to safer alternatives should be considered. Interleukin (IL)-17, IL-12/23, and IL-23 inhibitors are associated with low infection risk, with IL-17 and IL-23 favored over IL-12/23 inhibitors. Pivotal trials and postmarketing data also suggest ...
Ref: Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic [Dermatol Ther, 2020]IL-6 and TNF-α) are downstream of the TLR4 signaling pathway (38).
... targeting this motif of TLR4 might be a promising strategy to limit TLR4 activation induced by SARS-CoV-2. It is noteworthy that the main cytokines involved in severe COVID-19 cases ( IL-6 and TNF-α) are downstream of the TLR4 signaling pathway (38). ...
Ref: Is Toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities? [Cytokine Growth Factor Rev, 2020-09-21]IL-6 signals through two main inflammatory pathways referred to as cis-signaling or trans-signaling [7] .
... pg/mL; IQR 30.63-202.9 pg/mL) than the other four patients (median 109 pg/mL; IQR 108-160 pg/mL). IL-6 signals through two main inflammatory pathways referred to as cis-signaling or trans-signaling [7] . While cis-signaling activates acquired and innate immunity, trans-signaling can result in the dysfunction of endothelial ...
Ref: Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series [Respir Investig, 2020-10-07]interleukin (IL)-1ß, IL-6, monocyte chemoattractant peptide (MCP)-1,
... the respiratory epithelium. Interleukins that cause the chronic low-grade inflammatory state of obesity, such as interleukin (IL)-1ß, IL-6, monocyte chemoattractant peptide (MCP)-1, and, in particular, IL-17A and tumour necrosis factor alpha (TNF-α), also play very important roles ...
Ref: cord_uid vewnpj5a IL-17A and TNF-α as potential biomarkers for a... vewnpj5a IL-17A and TNF-α as potential biomarkers for a... Name: title, dtype: object [Respir Investig, cord_uid vewnpj5a 2020 vewnpj5a 2020 Name: publish_time, dtype: object]